E. Leray, T. Moreau, A. Fromont, and G. Edan, Epidemiology of multiple sclerosis, Rev Neurol (Paris), vol.172, issue.1, pp.3-13, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01255824

A. Fromont, C. Binquet, L. Clerc, and T. Moreau, Épidémiologie de la sclérose en plaques : la particularité française, Rev Neurol (Paris), vol.165, issue.8, pp.671-676, 2009.

, Définition et chiffres -Fondation Sclérose en plaques

D. Sur, La sclérose en plaques -Historique, épidémi, p.10

A. Compston and A. Coles, Multiple sclerosis, Lancet Lond Engl. avr, vol.359, issue.9313, pp.1221-1252, 2002.
URL : https://hal.archives-ouvertes.fr/hal-00996686

N. A. Patsopoulos, Genetics of multiple sclerosis: an overview and new directions, Cold Spring Harb Perspect Med, vol.8, issue.7, 2018.

S. Sawcer, R. Franklin, and M. Ban, Multiple sclerosis genetics, Lancet Neurol

J. L. Haines, H. A. Terwedow, K. Burgess, M. A. Pericak-vance, J. B. Rimmler et al., Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity, Hum Mol Genet, vol.7, issue.8, pp.1229-1263, 1998.

D. A. Compston, J. R. Batchelor, and W. I. Mcdonald, B-lymphocyte alloantigens associated with multiple sclerosis, Lancet Lond Engl, vol.2, issue.7998, pp.1261-1266, 1976.

T. Group, L. F. Barcellos, J. R. Oksenberg, A. J. Green, P. Bucher et al., Genetic basis for clinical expression in multiple sclerosis, Brain, vol.125, issue.1, pp.150-158, 2002.

H. Schmidt, D. Williamson, and A. Ashley-koch, HLA-DR15 haplotype and multiple sclerosis: a huge review, Am J Epidemiol, vol.165, issue.10, pp.1097-109, 2007.

A. Fogdell-hahn, A. Ligers, M. Grønning, J. Hillert, O. Olerup et al., Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease, 13. International Multiple Sclerosis Genetics Consortium, vol.55, pp.851-62, 2000.

N. Patsopoulos, S. E. Baranzini, A. Santaniello, P. Shoostari, and C. Cotsapas, The multiple sclerosis genomic map: role of peripheral immune cells and resident microglia in susceptibility, Consorti -International Multiple Sclerosis Genetics, p.143933, 2017.

C. O'gorman, R. Lin, J. Stankovich, and S. A. Broadley, Modelling genetic susceptibility to multiple sclerosis with family data, Neuroepidemiology, vol.40, issue.1, pp.1-12, 2013.

I. Kiselev, V. Bashinskaya, N. Baulina, M. Kozin, E. Popova et al., Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability, Mult Scler Relat Disord, vol.29, pp.130-136, 2019.

C. R. Gale and C. N. Martyn, Migrant studies in multiple sclerosis, Prog Neurobiol, vol.47, issue.4-5, pp.425-473, 1995.

P. Cabre, A. Signate, S. Olindo, H. Merle, D. Caparros-lefebvre et al., Role of return migration in the emergence of multiple sclerosis in the French West Indies, Brain, vol.128, issue.12, pp.2899-910, 2005.

J. G. Mcleod, S. R. Hammond, and J. F. Kurtzke, Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration, J Neurol, vol.258, issue.6, pp.1140-1149, 2011.

L. Michel, Environmental factors in the development of multiple sclerosis, Rev Neurol (Paris), vol.174, issue.6, pp.372-379, 2018.

S. Simpson, L. Blizzard, P. Otahal, I. V. Mei, . Der et al., Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, J Neurol Neurosurg Psychiatry, vol.82, issue.10, pp.1132-1173, 2011.

M. Niino, T. Fukazawa, S. Kikuchi, and H. Sasaki, Therapeutic potential of vitamin D for multiple sclerosis, Curr Med Chem, vol.15, issue.5, pp.499-505, 2008.

S. V. Ramagopalan, A. Heger, A. J. Berlanga, N. J. Maugeri, M. R. Lincoln et al., A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution, Genome Res, vol.20, issue.10, pp.1352-60, 2010.

C. Pierrot-deseilligny and J. Souberbielle, Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?, Brain, vol.133, issue.7, pp.1869-88, 2010.

C. Pierrot-deseilligny, Clinical implications of a possible role of vitamin D in multiple sclerosis, J Neurol, vol.256, issue.9, pp.1468-79, 2009.

M. T. Kampman, T. Wilsgaard, and S. I. Mellgren, Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle, 27. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25, vol.254, pp.471-478, 2007.

, Hydroxyvitamin D levels in serum at the onset of multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.11, issue.3, pp.266-71, 2005.

M. Soilu-hänninen, M. Laaksonen, I. Laitinen, J. Erälinna, E. Lilius et al., A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.79, issue.2, pp.152-159, 2008.

J. Correale, M. C. Ysrraelit, and M. I. Gaitán, Immunomodulatory effects of vitamin D in multiple sclerosis, Brain, vol.132, issue.5, pp.1146-60, 2009.

J. Smolders, P. Menheere, A. Kessels, J. Damoiseaux, and R. Hupperts, Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.14, issue.9, pp.1220-1224, 2008.

S. Simpson, B. Taylor, L. Blizzard, A. Ponsonby, F. Pittas et al., Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis, Ann Neurol, vol.68, issue.2, pp.193-203, 2010.

E. M. Mowry, E. Waubant, C. E. Mcculloch, D. T. Okuda, A. A. Evangelista et al., Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis, Ann Neurol, vol.72, issue.2, pp.234-274, 2012.

T. Riise, M. W. Nortvedt, and A. Ascherio, Smoking is a risk factor for multiple sclerosis, Neurology, vol.61, issue.8, p.1122, 2003.

R. Regal, A. Del-campo-amigo, M. Paz-esquete, J. , M. Feijoo et al.,

, Neurol Barc Spain, vol.24, issue.3, pp.177-80, 2009.

. Silva-krp-da, R. Alvarenga, Y. Fernandez, O. Fernandez, H. Alvarenga et al., Potential risk factors for multiple sclerosis in Rio de Janeiro: a case-control study, Arq Neuropsiquiatr, vol.67, issue.2A, pp.229-263, 2009.

M. A. Hernán, M. J. Oleky, and A. Ascherio, Cigarette smoking and incidence of multiple sclerosis, Am J Epidemiol, vol.154, issue.1, pp.69-74, 2001.

Y. Mikaeloff, G. Caridade, M. Tardieu, and S. Suissa, Parental smoking at home and the risk of childhood-onset multiple sclerosis in children, Brain, vol.130, issue.10, pp.2589-95, 2007.

A. K. Hedström, M. Bäärnhielm, T. Olsson, and L. Alfredsson, Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.7, pp.788-93, 2011.

J. Correale and M. F. Farez, Smoking worsens multiple sclerosis prognosis: two different pathways are involved, J Neuroimmunol, vol.281, pp.23-34, 2015.

R. Ramanujam, A. Hedström, A. Manouchehrinia, L. Alfredsson, T. Olsson et al., Effect of Smoking Cessation on Multiple Sclerosis Prognosis, JAMA Neurol, vol.72, issue.10, pp.1117-1140, 2015.

H. H. Balfour, S. K. Dunmire, and K. A. Hogquist, Infectious mononucleosis, Clin Transl Immunol, vol.4, issue.2, p.33, 2015.

P. F. Bray, L. C. Bloomer, V. C. Salmon, M. H. Bagley, and P. D. Larsen, Epstein-Barr Virus Infection and antibody synthesis in patients with multiple sclerosis, Arch Neurol, vol.40, issue.7, pp.406-414, 1983.

C. V. Sumaya, L. W. Myers, and G. W. Ellison, Epstein-Barr Virus antibodies in multiple sclerosis, Arch Neurol, vol.37, issue.2, pp.94-100, 1980.

A. E. Handel, A. J. Williamson, G. Disanto, L. Handunnetthi, G. Giovannoni et al., An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis, PLOS ONE. 1 sept, vol.5, issue.9, p.12496, 2010.

O. Santiago, J. Gutierrez, A. Sorlozano, J. De-dios-luna, E. Villegas et al., Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production, Eur J Clin Microbiol Infect Dis, vol.29, issue.7, pp.857-66, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00589489

S. Alotaibi, J. Kennedy, R. Tellier, D. Stephens, and B. Banwell, Epstein-Barr virus in pediatric multiple sclerosis, JAMA, vol.291, issue.15, pp.1875-1884, 2004.

L. I. Levin, K. L. Munger, E. J. O'reilly, K. I. Falk, and A. Ascherio, primary infection with the Epstein-Barr virus and risk of multiple sclerosis, Ann Neurol, vol.67, issue.6, pp.824-854, 2010.

P. Cabre, Environmental changes and epidemiology of multiple sclerosis in the French West Indies, J Neurol Sci, vol.286, issue.1, pp.58-61, 2009.

J. Correale and M. F. Farez, Parasite infections in multiple sclerosis modulate immune responses through a retinoic acid-dependent pathway, J Immunol, vol.191, issue.7, pp.3827-3864, 2013.

J. Sigaux, L. Semerano, G. Favre, N. Bessis, M. Boissier et al., rhumatismes inflammatoires et auto-immunité, Rev Rhum, vol.85, issue.1, pp.19-24, 2018.

P. Fayemendy, J. C. Desport, J. Cornu, O. Ragi, and P. Jésus, Nutrition et sclérose en plaques : le point de la littérature, Nutr Clin Métabolisme, vol.32, issue.1, pp.67-80, 2018.

, Qu'est-ce que la sclérose en plaques ?, Sclérose en plaques (SEP) [Internet]. Inserm

D. Sur,

V. Javalkar, J. Mcgee, and A. Minagar, Chapter 1 -Clinical nanifestations of multiple sclerosis: an overview, Minagar A, éditeur. Multiple Sclerosis

S. Diego,

J. Ouallet and B. Brochet, Aspects cliniques, physiopathologiques, et thérapeutiques de la sclérose en plaques, EMC -Neurol, vol.1, issue.4, pp.415-57, 2004.

F. D. Lublin and S. C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology, vol.46, issue.4, pp.907-918, 1996.

T. Moreau and G. Couvreur, La sclérose en plaques -PDF, 2019.

F. D. Disponible-sur-;-lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sørensen et al., Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.

D. Dimitri, MS: an inflammatory or a degenerative disease?, Neurologie.com

P. Bfgh, I. Pirko, and C. F. Lucchinetti, Pathology of multiple sclerosis: where so we stand?, Contin Lifelong Learn Neurol, vol.19, issue.4, pp.901-922, 2013.

H. Lassmann, W. Brück, and C. Lucchinetti, Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy, Trends Mol Med, vol.7, issue.3, pp.115-136, 2001.

I. Ifergan, Modulation de la réponse immunitaire dans le cerveau par la barrière hémato-encéphalique : implication en sclérose en plaques, 2012.

D. Sur,

C. Procaccini, D. Rosa, V. Pucino, V. Formisano, L. Matarese et al., Animal models of Multiple Sclerosis, Eur J Pharmacol, vol.759, pp.182-91, 2015.

B. Ajami, J. L. Bennett, C. Krieger, K. M. Mcnagny, and F. Rossi, Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool, Nat Neurosci, vol.14, issue.9, pp.1142-1151, 2011.

B. Nicol, M. Salou, D. Laplaud, and H. Wekerle, The autoimmune concept of multiple sclerosis, Presse Médicale, vol.44, issue.4, pp.103-115, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02147770

B. Bielekova, M. Catalfamo, S. Reichert-scrivner, A. Packer, M. Cerna et al., Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis, Proc Natl Acad Sci, vol.103, issue.15, pp.5941-5947, 2006.

K. Steinbach, M. Piedavent, S. Bauer, J. T. Neumann, and M. A. Friese, Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs, J Immunol, vol.191, issue.9, pp.4531-4540, 2013.

B. Aubé, S. A. Lévesque, A. Paré, É. Chamma, H. Kébir et al., Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases, J Immunol, vol.193, issue.5, pp.2438-54, 2014.

N. Couturier, J. P. Zappulla, V. Lauwers-cances, E. Uro-coste, M. Delisle et al., Mast cell transcripts are increased within and outside multiple sclerosis lesions, J Neuroimmunol, vol.195, issue.1, pp.176-85, 2008.

J. J. Rozniecki, S. L. Hauser, M. Stein, R. Lincoln, and T. C. Theoharides, Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients, Ann Neurol, vol.37, issue.1, pp.63-69, 1995.

M. Salou, E. Ngono, A. Garcia, A. Michel, L. Laplaud et al., Immunité adaptative et physiopathologie de la sclérose en plaques, Rev Médecine Interne, vol.34, issue.8, pp.479-86, 2013.

A. Compston, The pathogenesis and basis for treatment in multiple sclerosis, Clin Neurol Neurosurg, vol.106, issue.3, pp.246-254, 2004.

J. Goverman, Autoimmune T cell responses in the central nervous system, Nat Rev Immunol, vol.9, issue.6, pp.393-407, 2009.

J. M. Fletcher, S. J. Lalor, C. M. Sweeney, N. Tubridy, and K. Mills, T cells in multiple sclerosis and experimental autoimmune encephalomyelitis, Clin Exp Immunol, vol.162, issue.1, pp.1-11, 2010.

F. Petermann and T. Korn, Cytokines and effector T cell subsets causing autoimmune CNS disease, FEBS Lett, vol.585, issue.23, pp.3747-57, 2011.

A. E. Lovett-racke, Y. Yang, and M. K. Racke, Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?, Biochim Biophys Acta BBA -Mol Basis Dis, vol.1812, issue.2, pp.246-51, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00652650

F. Jadidi-niaragh and A. Mirshafiey, Th17 cell, the new player of neuroinflammatory process in multiple sclerosis, Scand J Immunol, vol.74, issue.1, pp.1-13, 2011.

T. Moreau and R. D. Pasquier, La sclérose en plaques, vol.300, 2017.

G. Martin-blondel, B. Pignolet, and R. S. Liblau, Migration et pathogénicité des lymphocytes T CD8 dans les maladies du système nerveux central. médecine/sciences, vol.31, pp.748-55, 2015.

C. Malmeström, J. Lycke, S. Haghighi, O. Andersen, L. Carlsson et al., Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF, J Neuroimmunol, vol.196, issue.1-2, pp.159-65, 2008.

R. Höftberger, F. Aboul-enein, W. Brueck, C. Lucchinetti, M. Rodriguez et al., Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions, Brain Pathol Zurich Switz, vol.14, issue.1, pp.1174-83, 2000.

E. Staun-ram and A. Miller, Effector and regulatory B cells in multiple sclerosis, Clin Immunol, vol.1, pp.11-25, 2017.

J. Masjuan, J. C. Alvarez-cermeño, N. García-barragán, M. Díaz-sánchez, M. Espiño et al., Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS, Neurology, vol.66, issue.4, pp.576-584, 2006.

R. J. Swingler and D. A. Compston, The morbidity of multiple sclerosis, Q J Med, vol.83, issue.300, pp.325-362, 1992.

D. Mcalpine and A. Compston, McAlpine's multiple sclerosis

A. Hennessey, N. P. Robertson, R. Swingler, and D. Compston, Urinary, faecal and sexual dysfunction in patients with multiple sclerosis, J Neurol, vol.246, issue.11, pp.1027-1059, 1999.

E. L. Koldewijn, O. R. Hommes, W. Lemmens, F. Debruyne, and P. Van-kerrebroeck, Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis, J Urol, vol.154, issue.1, pp.169-73, 1995.

F. Béthoux, Fatigue et sclérose en plaques, Ann Réadapt Médecine Phys, vol.49, issue.6, pp.265-71, 2006.

H. Zéphir, Fatigue et sclérose en plaques, Prat Neurol -FMC, vol.5, issue.1, pp.49-56, 2014.

J. D. Fisk, A. Pontefract, P. G. Ritvo, C. J. Archibald, and T. J. Murray, The impact of fatigue on patients with multiple sclerosis, Can J Neurol Sci J Can Sci Neurol, vol.21, issue.1, pp.9-14, 1994.

P. L. Foley, H. M. Vesterinen, B. J. Laird, E. S. Sena, L. A. Colvin et al.,

, Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis, Pain, vol.154, issue.5, pp.632-674, 2013.

S. A. Mcintosh-michaelis, M. H. Roberts, S. M. Wilkinson, I. D. Diamond, and D. L. Mclellan,

J. P. Martin, The prevalence of cognitive impairment in a community survey of multiple sclerosis, Br J Clin Psychol, vol.30, issue.4, pp.333-381, 1991.

M. A. Ron, M. M. Callanan, and E. K. Warrington, Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study, Psychol Med, vol.21, issue.1, pp.59-68, 1991.

B. Brochet, C. Lebrun-frénay, J. De-sèze, H. Zéphir, E. Allart et al., Chapitre 1 -Signes et symptômes de la sclérose en plaques

. Thérapeutique, , pp.3-78, 2017.

M. Deloire, E. Salort, M. Bonnet, Y. Arimone, M. Boudineau et al.,

, Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.76, issue.4, pp.519-545, 2005.

S. Huijbregts, N. F. Kalkers, L. De-sonneville, V. De-groot, I. Reuling et al., Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS, Neurology, vol.63, issue.2, pp.335-344, 2004.

S. B. Patten, C. A. Beck, J. Williams, C. Barbui, and L. M. Metz, Major depression in multiple sclerosis: a population-based perspective, Neurology, vol.61, issue.11, pp.1524-1531, 2003.

C. Lebrun and M. Cohen, Dépression et sclérose en plaques, Rev Neurol (Paris), vol.165, pp.156-62, 2009.

M. Korostil and A. Feinstein, Anxiety disorders and their clinical correlates in multiple sclerosis patients, Mult Scler Houndmills Basingstoke Engl, vol.13, issue.1, pp.67-72, 2007.

M. Damak, S. B. Nsir, E. Turki, I. Bouchhima, M. I. Miladi et al., Anxiété et dépression dans la sclérose en plaques : à propos de 100 patients tunisiens, Inf Psychiatr, vol.90, issue.5, pp.381-387, 2014.

L. Pfaff, D. Gounot, J. Lamy, N. Vincent, D. Seze et al., Modifications de l'expérience émotionnelle dans la sclérose en plaques : une étude en neuropsychologie et en IRMf, Rev Neurol (Paris), vol.174, pp.154-159, 2018.

, Troubles psychiques et neuropsychologiques dans la sclérose en plaques

, Académie nationale de médecine | Une institution dans son temps, 2003.

D. Sur,

, Sclérose en plaques

, Syndrome cliniquement isolé -la prise en charge thérapeutique

D. Sur,

A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee et al., Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, issue.2, pp.162-73, 2018.

R. Sharma, McDonald diagnostic criteria for multiple sclerosis: 2017 (current) | Radiology Reference Article | Radiopaedia.org

. Radiopaedia, , 2018.

D. Sur,

L. Freeman, C. Louapre, D. Galanaud, and B. Stankoff, Imagerie du système nerveux central dans la sclérose en plaques, Presse Médicale, vol.39, issue.3, pp.349-58, 2010.

W. I. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. Hartung et al., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, issue.1, pp.121-128, 2001.

F. Barkhof, M. Filippi, D. H. Miller, P. Scheltens, A. Campi et al., Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis, Brain, vol.120, issue.11, pp.2059-69, 1997.

J. K. Swanton, K. Fernando, C. M. Dalton, K. A. Miszkiel, A. J. Thompson et al., Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes, J Neurol Neurosurg Psychiatry, vol.77, issue.7, pp.830-833, 2006.

H. Link and Y. Huang, Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, J Neuroimmunol, vol.180, issue.1-2, pp.17-28, 2006.

A. Petzold, Intrathecal oligoclonal IgG synthesis in multiple sclerosis, J Neuroimmunol, vol.262, issue.1-2, pp.1-10, 2013.

M. Tintoré, A. Rovira, J. Río, C. Tur, R. Pelayo et al., Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis ?, Neurology, vol.70, issue.13, pp.1079-83, 2008.

L. Durante, W. Zaaraoui, A. Rico, L. Crespy, D. Wybrecht et al., Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual, Mult Scler Houndmills Basingstoke Engl, vol.18, issue.5, pp.587-91, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00826736

L. M. Villar, J. Masjuan, P. González-porqué, J. Plaza, M. C. Sádaba et al.,

, Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis, Ann Neurol, vol.53, issue.2, pp.222-228, 2003.

D. Ferraro, A. M. Simone, R. Bedin, V. Galli, F. Vitetta et al., Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome, J Neuroimmunol, vol.257, issue.1-2, pp.76-81, 2013.

S. Jarius, P. Eichhorn, D. Franciotta, H. F. Petereit, G. Akman-demir et al., The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature, J Neurol, vol.264, issue.3, pp.453-66, 2017.

M. M. Voortman, T. Stojakovic, L. Pirpamer, M. Jehna, C. Langkammer et al., Prognostic value of free light chains lambda and kappa in early multiple sclerosis, Mult Scler J, vol.23, issue.11, pp.1496-505, 2017.

G. Hinsinger, N. Galéotti, N. Nabholz, S. Urbach, V. Rigau et al., Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.21, issue.10, pp.1251-61, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01842463

N. Siller, J. Kuhle, M. Muthuraman, C. Barro, T. Uphaus et al., Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, p.1352458518765666, 2018.

M. Khademi, I. Kockum, M. Andersson, E. Iacobaeus, L. Brundin et al., Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course, Mult Scler Houndmills Basingstoke Engl, vol.17, pp.335-378, 2010.

R. M. Van-der-vuurst-de-vries, J. Y. Mescheriakova, T. F. Runia, N. Jafari, T. Siepman et al., Soluble CD27 levels in cerebrospinal fluid as a prognostic biomarker in clinically isolated syndrome, JAMA Neurol, vol.01, issue.3, pp.286-92, 2017.

T. Misu, T. Takahashi, I. Nakashima, K. Fujihara, and Y. Itoyama, Neuromyelitis optica and anti-aquaporin 4 antibody-distinct from multiple sclerosis, Rinsho Byori, vol.57, issue.3, pp.262-70, 2009.

M. S. Weber, T. Derfuss, I. Metz, and W. Brück, Defining distinct features of anti-MOG antibody associated central nervous system demyelination, Ther Adv Neurol Disord, vol.29, 2018.

, Sclérose en plaques | SEP -Procédure de diagnostic

D. Sur,

M. R. Khelouf, A. Benbakhti, H. Bouzenada, M. Nefti, M. Bendini et al., Les potentiels évoques visuels gardent-ils encore un intérêt diagnostique dans la sclérose en plaques ?, Rev Neurol, vol.172, p.87, 2016.

D. T. Okuda, E. M. Mowry, A. Beheshtian, E. Waubant, S. E. Baranzini et al., Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome, Neurology, vol.72, issue.9, pp.800-805, 2009.

C. Lebrun, Les syndromes radiologiquement isolés, Prat Neurol -FMC, vol.1, issue.1, pp.25-33, 2010.

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983.

, VIDAL -Sclérose en plaques -Prise en charge

D. Sur,

J. Cambier, M. Masson, C. Masson, ?. Dehen, and . Henri, 11 -Sclérose en plaques

. Paris, , pp.268-86, 2012.

L. Page, E. Deburghgraeve, V. Veillard, D. Edan, and G. , La prise en charge des poussées de sclérose en plaques en 2016, Prat Neurol -FMC, vol.7, issue.2, pp.166-73, 2016.

D. Fmpmc-ps--pharmacologie--niveau,

D. Sur,

I. Cortese, V. Chaudhry, Y. T. So, F. Cantor, D. R. Cornblath et al., Evidencebased guideline update : Plasmapheresis in neurologic disorders : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, vol.76, pp.294-300, 2011.

E. Masson, Traitements immunomodulateurs et immunosuppresseurs dans les maladies inflammatoires et auto-immunes

. Em-consulte,

D. Sur,

D. Sur,

A. Langer-gould, R. A. Popat, S. M. Huang, K. Cobb, P. Fontoura et al., Clinical and demographic predictors of long-term disability in patients with relapsingremitting multiple sclerosis: a systematic review, Arch Neurol, vol.63, issue.12, pp.1686-91, 2006.

O. Gout, C. Bensa, and R. Assouad, Actualités thérapeutiques de la sclérose en plaques, Rev Médecine Interne. 1 août, vol.31, issue.8, pp.575-80, 2010.

, Fiche info -AVONEX 30 microgrammes/0,5 ml, solution injectable -Base de données publique des médicaments

D. Sur,

, Fiche info -BETAFERON 250 microgrammes/ml, poudre et solvant pour solution injectable -Base de données publique des médicaments

D. Sur,

, Fiche info -EXTAVIA 250 microgrammes/ml, poudre et solvant pour solution injectable -Base de données publique des médicaments

D. Sur,

, Fiche info -REBIF 22 microgrammes, solution injectable en stylo prérempli -Base de données publique des médicaments

D. Sur,

, Fiche info -REBIF 44 microgrammes, solution injectable en seringue préremplie -Base de données publique des médicaments

D. Sur,

, Fiche info -PLEGRIDY 125 microgrammes, solution injectable en stylo prérempli -Base de données publique des médicaments

D. Sur,

, Quels sont les principaux effets indésirables des traitements par interféron bêta ?

. Lorsep, , 2016.

D. Sur, Interférons bêta dans le traitement de la sclérose en plaques: risque de microangiopathie thrombotique et de syndrome néphrotique -Lettre aux professionnels de santé -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

, TECFIDERA gélule gastrorésistante (diméthyle fumarate) : désormais disponible en ville

. Vidal,

D. Sur,

, Fiche info -TECFIDERA 240 mg, gélule gastro-résistante -Base de données publique des médicaments

L. Sabbah, 357 -Immunomodulateurs, Méga Guide STAGES IFSI, 2015.

I. Casetta, G. Iuliano, and G. Filippini, Azathioprine for multiple sclerosis, J Neurol Neurosurg Psychiatry. févr, vol.80, issue.2, pp.131-133, 2009.

F. Ashtari and M. R. Savoj, Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon ?-1?: A randomized controlled trial, J Res Med Sci Off J Isfahan Univ Med Sci, vol.16, issue.4, pp.457-62, 2011.

. Vidal--cellcept, 250 mg gél -Pharmacodynamie

D. Sur,

L. Pandit, S. Mustafa, C. Malli, D. Cunha, and A. , Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report, Neurol India, vol.62, issue.6, p.646, 2014.

, Mécanismes immunologiques des traitements de fond de la sclérose en plaques, Prat Neurol -FMC, vol.7, issue.2, pp.159-65, 2016.

R. Brandstadter, K. Sand, and I. , The use of natalizumab for multiple sclerosis, Neuropsychiatr Dis Treat, vol.13, pp.1691-702, 2017.

A. Chardain and B. Stankoff, Mécanisme d'action et applications thérapeutiques du fingolimod, MISE AU POINT, p.5

. Netgen, Sclérose en plaques : au-delà des traitements de première ligne

. Revue-médicale-suisse,

D. Sur,

, Sclérose en plaques : restrictions d'utilisation de LEMTRADA (alemtuzumab) face à la survenue d'effets secondaires graves

. Vidal,

D. Sur,

, Fiche info -MABTHERA 500 mg, solution à diluer pour perfusion -Base de données publique des médicaments

(. Rituximab and . Mabthera®, Résumé des caractéristiques du produit -MITOXANTRONE ACCORD 2 mg/mL, solution à diluer pour perfusion -Base de données publique des médicaments, Disponible sur, 2018.

D. Sur,

S. Vukusic, C. Renoux, L. Gignoux, F. Durand-dubief, I. Achiti et al., Mitoxantrone et sclérose en plaques : efficacité et tolérance chez 123 patients. /data/revues/00353787/0160SUP1/34, 2008.

D. Sur,

, Résumé des caractéristiques du produit -CYCLOPHOSPHAMIDE SANDOZ 500 mg, poudre pour solution injectable ou pour perfusion -Base de données publique des médicaments

A. Ben-haddou, E. Benomar, A. Ahid, S. Chatri, H. Slimani et al., Efficacité et tolérance du cyclophosphamide dans le traitement de fond des formes progressives de la sclérose en plaques, Rev Neurol (Paris), vol.165, issue.12, pp.1086-91, 2009.

, Prise en charge de la fatigue : sclérose en plaques

D. Sur,

, Atelier-Troubles-vesicaux-sphincteriens-Congres

D. Sur,

, La 4-aminopyridine (Fampridine) dans la SEP

, Fondation Charcot stichting, 2014.

D. Sur,

X. Moisset, Douleur et sclérose en plaques, Rev Neurol (Paris), vol.171, pp.205-211, 2015.

J. J. Feng and D. Ontaneda, Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies, Degener Neurol Neuromuscul Dis, vol.7, pp.31-45, 2017.

D. Sur,

L. Kappos, A. Bar-or, B. Cree, R. J. Fox, G. Giovannoni et al., Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study, The Lancet, vol.391, pp.1263-73, 2018.

, Nouvelle de dernière heure : la FDA approuve le siponimod pour le traitement de la SP progressive secondaire chez l'adulte -Société canadienne de la SP

D. Sur,

, Demyelinisation-remyelinisation, 2018.

D. Sur,

A. Tourbah, C. Lebrun-frenay, G. Edan, M. Clanet, C. Papeix et al., MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, doubleblind, placebo-controlled study, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.13, pp.1719-1750, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02153440

J. Chataway, N. Schuerer, A. Alsanousi, D. Chan, D. Macmanus et al., Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial, The Lancet, vol.383, issue.9936, pp.2213-2234, 2014.

R. J. Fox, C. S. Coffey, R. Conwit, M. E. Cudkowicz, T. Gleason et al., Nom et Prénom de l'auteur : LEPRIEUR Alexia Adresse de l'auteur : CAEN direct research towards new therapeutics, especially for the progressive form for which the health professionals remain deprived. This thesis thus makes an inventory of knowledge of the disease : factors and mechanisms, N Engl J Med, vol.379, issue.9, pp.846-55, 2018.

, Sclérose en plaques, facteurs, symptômes, diagnostic, traitements, avancées thérapeutiques